Análisis de la acción Achieve Life Sciences, Inc. (ACHV)ACHVAchieve Life Sciences, Inc.

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Achieve Life Sciences Inc (ACHV) appears to be a good buy right now, trading at $6.49 with a significant analyst price target of $18 from Stifel, indicating a potential upside of 177.4%. The company is advancing its cytisinicline drug for smoking cessation, which analysts believe has strong market potential. However, the stock has a low RSI of 29.212, indicating it is oversold, which could present a buying opportunity. The main risk is the company's negative earnings, with an EPS of -0.80 projected for the next quarter, which could affect short-term performance.

1 analysts cover ACHV: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 15.50.